DelistingApr 22, 2026, 05:11 PM
Apimeds Pharma Receives NYSE Delisting Notice for Late 10-K Filing
AI Summary
Apimeds Pharmaceuticals US, Inc. received a notice from NYSE Regulation on April 17, 2026, indicating non-compliance with continued listing requirements due to its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company has an initial six-month period to regain compliance by filing the Form 10-K. Apimeds expects to file the Form 10-K by April 30, 2026, but there is no assurance it will meet this date.
Key Highlights
- Received NYSE notice on April 17, 2026, for failure to file 2025 Form 10-K.
- Company has an initial six-month cure period from April 17, 2026.
- NYSE may grant an extension of up to six additional months if needed.
- Company expects to file the Form 10-K by April 30, 2026.
Price Impact
More from APUS